Tharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?

Tharimmune, Inc. (NASDAQ:THAR) shares shot up 8.9% on Friday . The stock traded as high as $2.48 and last traded at $2.45. 254,850 shares traded hands during trading, a decline of 93% from the average session volume of 3,476,183 shares. The stock had previously closed at $2.25.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on THAR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tharimmune in a report on Wednesday, October 8th. Wall Street Zen raised shares of Tharimmune from a “sell” rating to a “hold” rating in a research report on Sunday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Tharimmune Trading Up 8.9%

The company has a market cap of $85.85 million, a P/E ratio of -0.61 and a beta of 1.42. The business has a 50 day moving average price of $3.04 and a 200-day moving average price of $2.42.

Tharimmune (NASDAQ:THAR) last issued its earnings results on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.09.

Institutional Investors Weigh In On Tharimmune

Several hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Tharimmune during the second quarter worth approximately $25,000. Drucker Wealth 3.0 LLC acquired a new stake in shares of Tharimmune in the third quarter valued at approximately $29,000. Finally, Franklin Resources Inc. bought a new position in shares of Tharimmune during the 2nd quarter worth approximately $88,000. 1.16% of the stock is currently owned by institutional investors and hedge funds.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).